PCM
IPXL

Pennant Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Pennant Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,949,569
Closed -$56.2M – 49
2016
Q2 		$56.2M Sell
1,949,569
-133,505
-6% -$4.35M 1.44% 28
2016
Q1 		$66.7M Sell
2,083,074
-238,507
-10% -$8.38M 1.9% 29
2015
Q4 		$99.3M Sell
2,321,581
-722,200
-24% -$28.8M 2.53% 23
2015
Q3 		$107M Sell
3,043,781
-160,315
-5% -$7.22M 2.27% 23
2015
Q2 		$147M Buy
3,204,096
+1,179,096
+58% +$56M 2.92% 16
2015
Q1 		$94.9M Buy
2,025,000
+1,491,900
+280% +$59.4M 1.78% 23
2014
Q4 		$16.9M Buy
+533,100
New +$15.6M 0.32% 38

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pennant Capital Management's IPXL Position: Q3 2016 in Review

Pennant Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q3 2016, closing a stake of 1,949,569 shares — an estimated $56.2M sold.

Pennant Capital Management first reported a position in IPXL in Q4 2014 and held it in 7 quarters. The position peaked at $147M in Q2 2015. 196 funds tracked by Wall St. Rank hold IPXL as of Q3 2016.

  • Pennant Capital Management reported no remaining Impax Laboratories, Inc. position as of Q3 2016 after selling out during the quarter.
  • Pennant Capital Management sold 1,949,569 Impax Laboratories, Inc. shares in Q3 2016, an estimated $56.2M.
  • Pennant Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 7 quarters.
  • Pennant Capital Management's Impax Laboratories, Inc. position peaked at $147M in Q2 2015.
  • 196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2016.

Based on Pennant Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.